NAMS
NewAmsterdam Pharma Company N.V
$38.73
+11.13%
2026-05-08
About NewAmsterdam Pharma Company N.V
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Key Fundamentals
Forward P/E
-26.97
EPS (TTM)
$-1.78
ROE
-28.3%
Revenue Growth (YoY)
-99.8%
Profit Margin
0.0%
Debt/Equity
0.03
Price/Book
6.20
Beta
0.03
Market Cap
$4.33B
Avg Volume (10D)
1.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$41.17
60D Low
$27.85
Avg Volume
974K
Latest Close
$38.73
Get breakout alerts for NAMS
Sign up for Breakout Scanner to receive daily notifications when NAMS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
NewAmsterdam Pharma Company N.V (NAMS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NAMS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NAMS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.